GranuFlo and Heart Attacks

Fresenius Medical Care (FMC), the manufacturer of GranuFlo and NaturaLyte acid concentrates, has reported that patients undergoing hemodialysis treatment with those products face an increased risk of experiencing heart attacks and other severe side effects such as stroke, myocardial infarction, metabolic alkalosis, cardiopulmonary arrest, and death.

In November 2011, Fresenius Medical Care released an internal memo warning that dialysis patients receiving treatment GranuFlo and NaturaLyte products are six times more likely to suffer heart attacks than patients receiving treatment with other dialysis products. Fresenius also reported that 941 hemodialysis patients had suffered cardiac arrest inside FMC clinics in 2010 after using GranuFlo and NaturaLyte products. The memo included evidence that the high bicarbonate blood levels caused by GranuFlo and NaturaLyte are linked to an increased risk of heart attack and stroke.

Fresenius Medical Care released this internal memo to Fresenius-owned dialysis centers, but failed to warn thousands of other physicians working in centers not owned by FMC. The U.S. Food and Drug Administration (FDA) issued a Class 1 recall of all GranuFlo and NaturaLyte hemodialysis products after receiving a copy of the leaked internal memo in March 2012.

If you or a loved one experienced a heart attack after receiving hemodialysis treatment with GranuFlo and NaturaLyte, you may be eligible to file a lawsuit. Contact the dialysis injury attorneys at Hissey Kientz, LLP for a free case evaluation by calling toll-free at 1-866-275-4454, or by filling out our free contact form on the right of this page.


I am currently represented by an attorney
*Required fields